Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that while levodopa remains the gold standard for Parkinson's disease treatment, physicians say they will increasingly use other agents to delay the need for levodopa. According to the new report entitled Treatment Algorithms in Parkinson's Disease, 46 percent of surveyed neurologists say it is "very likely" or "likely" they will increasingly delay their use of levodopa-carbidopa in treatment practice over the next two years. In the U.S., levodopa and carbidopa are prescribed together.

Physicians are looking to delay levodopa use because over time, treatment with levodopa can lead to motor fluctuations, dyskinesia and reduced responsiveness to levodopa. Compared with primary care physicians, surveyed neurologists less frequently use levodopa as first-line therapy for patients with mild disease under the age of 65 and are increasingly using dopamine agonists and MAO-B inhibitors to manage mild motor symptoms and delay the need for levodopa. At the same time, more than half of surveyed primary care physicians say that it is "very likely" or "likely" they will increasingly use dopamine agonists and/or MAO-B inhibitors when initiating levodopa therapy in order to lower the dose of levodopa-carbidopa required.

"Since all Parkinson's disease patients are ultimately treated with levodopa, educating primary care physicians on the merits of levodopa-adjunct therapies like dopamine agonists and MAO-B inhibitors should help drug marketers drive greater uptake of these therapies," said Decision Resources Analyst Sami Fam, Ph.D. "In particular, education about the benefits of delaying levodopa therapy in young Parkinson's disease patients is key, since this patient population is the one most likely to be under the care of a primary care physician."

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from IMS LifeLink's Health Plans Claims database to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Decision Resources                           Decision Resources, Inc.   Lisa Osgood                                  Chris Comfort   781-296-2606                                 781-296-2597                  

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Lisa Osgood, Decision Resources, +1-781-296-2606,, or Chris Comfort, Decision Resources, Inc.,

New Study By BioTrends Highlights the Risk of TNF-alpha Inhibitors of Losing Patient Share To Alternative Mechanism Agents in the Treatment of Rheumatoid Arthritis

View Now